Skip to content
value.today

Lysosomal Therapeutics, Inc.

🇺🇸 Cambridge, Massachusetts, USAPharmaceuticalsFounded 2011
Total raised
$38 M
4 rounds on record
Latest round
$1 M
Oct 2019
First round on record
Apr 2014
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Lysosomal Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2019$1 MNo. 4Under $2 million

Lysosomal Therapeutics, Inc.: Raise no. 4, Oct 2019

Investors in this round

10 investors had bought by the notice of Nov 7, 2019: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cornelis Been · Executive Officer, Director
  • Daniel Geffken · Executive Officer
  • Robert Carpenter · Executive Officer, Director
  • Bruce L. Booth · Director
  • Carole E. Nuechterlein · Director
  • Clay E. Thorp · Director
  • Steven E. Hall · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cornelis Been, President & CEO. Newest notice filed Nov 7, 2019. Read the notice at the SEC.

debt, optionsSEC
Oct 2016$6 MNo. 3$2 to $10 million

Lysosomal Therapeutics, Inc.: Raise no. 3, Oct 2016

Investors in this round

9 investors had bought by the notice of Oct 6, 2016: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$250,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cornelis Been · Executive Officer, Director
  • Robert Carpenter · Executive Officer, Director
  • Bernard Davitian · Director
  • Bruce Booth · Director
  • Carole Nuechterlein · Director
  • Clay Thorp · Director
  • Steven Hall · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cornelis Been, President & CEO. Newest notice filed Oct 6, 2016. Read the notice at the SEC.

debt, optionsSEC
Jan 2015$26 MNo. 2$10 to $50 million

Lysosomal Therapeutics, Inc.: Raise no. 2, Jan 2015

Investors in this round

9 investors had bought by the notice of Jan 18, 2017: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cornelis Been · Executive Officer, Director
  • Daniel Geffken · Executive Officer
  • Robert Carpenter · Executive Officer, Director
  • Bernard Davitian · Director
  • Bruce Booth · Director
  • Carole Neuchterlein · Director
  • Clay Thorp · Director
  • Steven Hall · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cornelis Been, President & CEO. Newest notice filed Jan 18, 2017 (1 amendment). Read the notice at the SEC.

equitySEC
Apr 2014$5 MNo. 1$2 to $10 million

Lysosomal Therapeutics, Inc.: Raise no. 1, Apr 2014

Investors in this round

11 investors had bought by the notice of May 13, 2014: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cornelis Been · Executive Officer, Director
  • Robert Carpenter · Executive Officer, Director
  • Dimitri Krainc · Director
  • Henri Termeer · Director
  • Peter Wirth · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Cornelis Been, President and CEO. Newest notice filed May 13, 2014. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Lysosomal Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2019).

    SEC Form D · Nov 2019

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Lysosomal Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Lysosomal Therapeutics, Inc.
NameRoleNamed in
Cornelis BeenExecutive officerNov 2019
Daniel GeffkenExecutive officerNov 2019
Robert CarpenterExecutive officerNov 2019
Bruce L. BoothDirectorNov 2019
Carole E. NuechterleinDirectorNov 2019
Clay E. ThorpDirectorNov 2019
Cornelis BeenDirectorNov 2019
Robert CarpenterDirectorNov 2019
Steven E. HallDirectorNov 2019
Bernard DavitianDirectorJan 2017
Bruce BoothDirectorJan 2017
Carole NeuchterleinDirectorJan 2017
Clay ThorpDirectorJan 2017
Steven HallDirectorJan 2017
Carole NuechterleinDirectorOct 2016
Dimitri KraincDirectorMay 2014
Henri TermeerDirectorMay 2014
Peter WirthDirectorMay 2014